NGM Biopharmaceuticals and Merck have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a range of therapeutic areas.   The collaboration includes multiple drug candidates currently in preclinical development at NGM, including NP201 being evaluated for the treatment of diabetes, obesity and nonalcoholic steatohepatitis (NASH). NGM will lead R&D for existing preclinical candidates and pursue other discovery stage programs....